3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
9
Neoplasms
8
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Polycythemia Vera
1
Pathologic Complete Response
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Interventions
talazoparib
1
olaparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
talazoparib
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled